FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 2054

19	OMB APP	OMB APPROVAL					
	 OMP North and	2005					

OMB Number:	3235-028
Estimated average bure	den
hours per response.	0.4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* DOYLE MICHAEL A (Last) (First) (Middle) C/O FORRESTER RESEARCH, INC. 60 ACORN PARK DRIVE (Street) CAMBRIDGE MA 02140 (City) (State) (Zip)				3. I 11/	2. Issuer Name and Ticker or Trading Symbol FORRESTER RESEARCH, INC. [FORR] 3. Date of Earliest Transaction (Month/Day/Year) 11/03/2020 4. If Amendment, Date of Original Filed (Month/Day/Year)								X X	Chief Financial Officer Individual or Joint/Group Filing (Check Applicable ne)					
		Tab	le I - N	on-Deri	vative	e Sec	urit	ies Ac	quire	d, Di	sposed o	f, or Be	nefici	ally	Owned				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/					on 2A. Deemed Execution Date,		3. 4. Securities		es Acquired (A) or Of (D) (Instr. 3, 4 a		5. Amou Securiti Benefic Owned		es Following (I)		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
									Code V		Amount	(A) or (D)	Price			ansaction(s) str. 3 and 4)			(Instr. 4)
Common	Stock			11/03/	2020)20		М		14,000	A	\$33.	03	58,	8,429		D		
Common	Stock			11/03/	2020				S	s 14,000 D \$38.8987 44,429		,429		D					
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Derivative (Instr. 3) 3. Transaction Date (Month/Day/Year) 3. Transaction Date Execution Date, if any (Month/Day/Year) (Month/Day/Year) 4. Transaction Date (Month/Day/Year) (Month/Day/Year)					outs, 4. Transa	uts, calls, warrants . ransaction of ode (Instr.) Derivative Securities Acquired			quired, Disposed of, s, options, convertible 6. Date Exercisable and Expiration Date (Month/Day/Year)					8. Di	Price of erivative ecurity nstr. 5)			10. Ownership Form: Direct (D) or Indirect	Beneficial Ownership (Instr. 4)
Security					(A) or Disposed of (D) (Instr. 3, 4 and 5)			and 4)			(ilisti. 3			(I) (Instr. 4)					
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amour or Number of Shares	er		,			
Non Qualified Stock Option (Right to Buy)	\$33.03	11/03/2020			M			14,000	04/01/2	2015	06/30/2021	common stock	14,00	0	\$33.03	0		D	

Explanation of Responses:

Remarks:

Maite Garcia, attorney-in-fact for Michael Doyle

11/05/2020

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- I hereby constitute and appoint each of Ryan Darrah, Maite Garcia and Jed Rosenkrantz signing singly, my true and lawful attorney-in-fact to:
- (1) execute for and on my behalf, in my capacity as an officer and/or director of Forrester Research, Inc. (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (2) do and perform any and all acts for and on my behalf that may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be to my benefit, in my best interest, or that I am legally required to do, it being understood that the documents executed by such attorney-in-fact on my behalf pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

I hereby grant to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as I might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. I acknowledge that the attorney-in-fact, in serving in such capacity at my request, are not assuming, nor is the Company assuming, any of my responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until I am no longer required to file Forms 3, 4 and 5 with respect to my holdings of and transactions in Company securities, unless I earlier revoke it in a signed writing delivered to the attorneys-in-fact. Upon signature of this Power of Attorney, I hereby revoke all previous powers of attorney granted concerning the subject matter herein.

IN WITNESS WHEREOF, I have caused this Power of Attorney to be executed as of this May 16, 2018.

/s/ Michael Doyle Signature

Michael Doyle Print Name